

CURRICULUM VITAE

JOSEPH M. CONEY, MD

OFFICE ADDRESSES

Retina Associates of Cleveland, Inc.
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122
14725 Detroit Avenue, Suite 200; Cleveland, Ohio 44107
15299 Bagley Road, Suite 200; Cleveland, Ohio 44130
17534 Royalton Road, Suite 201; Cleveland, Ohio 44136
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052
690 White Pond Drive, Suite 120; Akron, Ohio 44320
170 North Street NE; Warren, Ohio 44483
5390 Belmont Avenue; Youngstown, Ohio 44505
708 N Jefferson Street; New Castle, Pennsylvania 16101

TELEPHONE

216-831-5700

WEBSITE

www.retina-doctors.com

EDUCATION

College

University of Illinois
Champaign, Illinois
1990–1994, BS (Biology)

Medical School

Loyola-Stritch School of Medicine
Maywood, Illinois
1995–1999, MD

POSTGRADUATE TRAINING

Internship

Transitional
Resurrection Medical Center
Chicago, Illinois
1999–2000

Residency

Ophthalmology
Case Western Reserve University
Cleveland, Ohio
2000–2003

Fellowship

Medical Retina Fellowship
Joslin Diabetes Center—an affiliate of Harvard Medical School
Boston, Massachusetts
2003–2004

Surgical Retina Fellowship (2 years)
Vitreoretinal Foundation
Memphis, Tennessee
2004–2006

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio and Pennsylvania

Diplomate, American Board of Ophthalmology, 2006

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 2006–

Private practice in vitreoretinal surgery and diseases. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G. Miller, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD; Lili G. Kaplan, MD; Shawn A. Lewis, MD

National Medical Association

Incoming Chair, Executive Committee Member, Ophthalmology Section, 2014 & 2015
President, Ophthalmology Section, 2013–2015
President-elect, Ophthalmology Section, 2011–2013
Councilor to the American Academy of Ophthalmology Council, 2009–2013
Chair, Retina Section, 2009–2012
Postgraduate Section liaison, 2005–
Board of Directors, Ophthalmology Section, 2005–
Secretary, Ophthalmology Section, 2005–2012

American Academy of Ophthalmology

Member, Knowledge Base Subcommittee - Retina/Vitreous Panel, 2013–
Selected participant, Leadership Development Program, 2007–2008
Project: National Medical Association Health Fair and Eye Care America Initiative

Ohio Ophthalmological Society

Vice President, 2016–
Secretary/Treasurer, 2014–2016
Board of Directors, District 5 Representative, 2012–

Cleveland Ophthalmological Society

President, 2014–2015
President-elect, 2013–2014
Vice-president, 2012–2013
Secretary, 2011–2012

Diabetes Partnership of Cleveland (formerly the Diabetes Association of Greater Cleveland)

Co-chair, Program Committee, 2013–

Board of Directors, 2006–

Eyeteck Inc.

Clinical Advisory Board, 2008–2010

Allergan

US Retina Regional Scientific Advisory Board, 2012–

Clinical Advisory Board, 2010–2011

Genentech

Lucentis Business Strategy National Advisory Board, 2012–

Retina Specialist Speakers Bureau, 2012–

Thrombogenics

Regional Council on Ocriplasmin, 2013–

ACADEMIC APPOINTMENTS

Senior Clinical Instructor, Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine/University Hospitals of Cleveland, Cleveland, Ohio, November 2008–

OTHER ACADEMIC AND ADMINISTRATIVE POSITIONS

Resident Mentor, 2003–2004

Massachusetts General Hospital

Mentor Coordinator, 1996

Robert Wood-Johnson Foundation, Minority Medical Education Program

Inter-Fraternal Greek Council, 1993–1995

Board of Fraternity Affairs, University of Illinois at Urbana-Champaign

Chapter President (Polmarch), 1992–1994

Kappa Alpha Psi Fraternity, University of Illinois at Urbana-Champaign

Minority Organization for Pre-Health Students, 1992–1994

University of Illinois at Urbana-Champaign

Chapter President, 1993–1994

Chapter Treasurer, 1992–1993

PROFESSIONAL SOCIETIES AND COMMITTEES

Vit-Buckle Society, 2013–

American Eye Study Club, 2010–
American Society of Retinal Specialists, 2007–
Roman-Barns Society of Ophthalmology, 2007
Ohio State Medical Association, 2007–
Academy of Medicine of Cleveland and Northern Ohio, 2007–
Diabetes Association of Greater Cleveland, 2007–
Cleveland Ophthalmologic Society, 2000–2003, 2006–
Ohio Ophthalmological Society, 2006–
Endocrine Society, 2002–
United States Boxing Federation Fight Doctor, 2001–
American Academy of Ophthalmology, 2000–
Cook County Physicians Association, 1996–2001
American Medical Association, 1996–

Student National Medical Association, 1995–1999
 Chairman of National Convention, 1997–1998
 Member Board of Directors, 1997–1998
 Local Chapter President, 1997–1998
 Local Chapter, Treasurer 1995–1996
 National Delegate, 1995–1999
 Region II Delegate, 1995, 1996, 1999
 Region II Fundraiser Coordinator, 1996–1997

Medical Student Union Representative, 1995–1999
 Loyola-Stritch School of Medicine

Primary Care Committee Chair, 1995
 American Medical Student Association

University of Illinois Alumni Association, 1995–

Kappa Alpha Psi Fraternity Inc., 1992–

HONORS AND AWARDS

Top Doctors, 2015, 2016

Special Recognition Award, 2013

American Academy of Ophthalmology Leadership Development Program

Service Award, 2013

National Medical Association, Toronto, Ontario, Canada

Service Award, 2011

National Medical Association, Washington, DC

America's Top Ophthalmologists, Consumers Research Council of America, 2007

Cambridge Who's Who of Executives and Professionals, Honored Life Time Member, 2007

Service Award, 2006

National Medical Association; Dallas, Texas

Rabb-Venable Award for Outstanding Fellow Research Presentation, 2004

National Medical Association; San Diego, California

Rabb-Venable Award for Outstanding Resident Research Presentation, 2003

National Medical Association; Philadelphia, Pennsylvania

Outstanding Resident Research Award, 2003

Case Western Reserve University; Cleveland, Ohio

Janice Douglas-David Satcher Clerkship, 1999

Case Western Reserve University; Cleveland, Ohio

National Merit Award, 1995

Student National Medical Association

Member of the Year, 1995

Student National Medical Association

Cook County Physicians Association Scholarship Recipient, 1995

Chicago, Illinois

Dean's List, College of Liberal Arts & Science, 1990–1993

University of Illinois; Champaign, Illinois

Delta Sigma Theta Scholarship Recipient, 1991

Alpha Lambda Delta National Honor Society, 1990

University of Illinois; Champaign, Illinois

Phi Eta Sigma Freshman Honor Society, 1990

University of Illinois; Champaign, Illinois

HOSPITAL & ASC AFFILIATIONS

Akron General Medical Center, Akron, Ohio
Austintown Surgery Center / *Surgery Center* of Canfield; Canfield, Ohio
Lippy Surgery Center; Warren, Ohio
Summa Health; Akron, Ohio
University Hospitals of Cleveland; Cleveland, Ohio

RESEARCH ACTIVITIES

NIH-funded Grants

DRCRnet Protocol V. Treatment for central involved diabetic macular edema in eyes with very good visual acuity
Co-investigator, 2014–

DRCRnet Protocol U. Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes
Co-investigator, 2014–

Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2)
Co-investigator, 2014–

DRCRnet Protocol S. Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy
Co-investigator, 2012–

DRCRnet Genes in Diabetic Retinopathy Project
Co-investigator, 2012–

DRCRnet Protocol T. Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for diabetic macular edema
Co-investigator, 2012–2015

Home vision monitoring in AREDS2 for progression to neovascular AMD using the ForeseeHome device
Co-investigator, 2011–2013

DRCRnet Protocol M. Effect of diabetes education during retinal ophthalmology visits on diabetes control
Co-investigator, 2011–

DRCRnet Protocol R. Phase II evaluation of topical NSAIDS on eyes with non-central involved DME
Co-investigator, 2011–2013

DRCRnet Protocol N. Evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy

Co-investigator, 2010–2012

DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema

Co-investigator, 2009–2010

Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)

Co-investigator, 2008–2012

DRCRnet Protocol I. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema

Co-investigator, 2007–2014

DRCRnet Protocol K. Course of response to focal photocoagulation for diabetic macular edema

Co-investigator, 2007–2008

Age-Related Eye Disease Study (AREDS) 2

Co-investigator, 2006–2012

Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

Co-investigator, 2006–2009

Other National Clinical Trials

A 2-year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 (small interfering RNA) in subjects with subfoveal CNV secondary to AMD (SIRIUS)

Principal investigator, 2006–2008

Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)

Principal Investigator, 2016–

Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)

Co-investigator, 2015–

Phase III double-masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration

Co-investigator, 2015–

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2015–

An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)

Co-investigator, 2015–

LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration

Co-investigator, 2015–

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH-258 versus aflibercept in subjects with neovascular age-related macular degeneration

Co-investigator, 2015–

A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)

Co-investigator, 2015–

Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)

Co-investigator, 2015–

Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema

Co-investigator, 2014–2015

A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)

Co-investigator, 2014–

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2013–

Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)

Co-investigator, 2013–

Phase 2 multicenter randomized clinical trial of ciliary neurotrophic factor (CNTF) for macular telangiectasia type 2 (Mactel CNTF 2)

Co-investigator, 2013–

Prospective, two-cohort, single-masked study to evaluate the effect of ESBA1008 applied by microvolume injection or infusion in subjects with exudative age-related macular degeneration

Co-investigator, 2013–2015

Prospective, randomized, double-masked, multicenter, two arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration

Co-investigator, 2013–2014

Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration

Co-investigator, 2012–2015

Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration

Co-investigator, 2012–2013

Safety and efficacy study of gevokizumab to treat active non-infectious uveitis (EYEGUARD™-A)

Co-investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat non-infectious uveitis controlled with systemic treatment (EYEGUARD™-C)

Co-investigator, 2012–2015

Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration

Co-investigator, 2012

A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration

Co-investigator, 2012–

Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)

Co-investigator, 2012–2014

Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (Mactel)

Co-investigator, 2011–

A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy (Genentech)

Co-investigator, 2011–2013

Multicenter, 2 stage (open label, dose escalation, followed by masked, randomized) single dose study of the safety and efficacy of AGN-208397 in patients with macular edema (ME) associated with retinal vein occlusion (RVO)

Co-investigator, 2011–2012

Multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of voclosporin as therapy in subjects with active noninfectious intermediate, posterior, or pan-uveitis

Co-investigator, 2011–2013

Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration

Co-investigator, 2010–2011

Phase II, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis in subjects with neovascular age related macular edema (Ophthotech 1001)

Co-investigator, 2010–2011

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–2012

Phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR) (Genentech)

Co-investigator, 2009–2012

Geographic Atrophy Treatment Evaluation (GATE) Study

Co-investigator, 2009–2012

Phase 1a, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy

Co-investigator, 2009–2010

Phase II, randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema

Co-investigator, 2009–2010

Natural History of Geographic Atrophy Progression (GAP) Study

Co-investigator, 2008–2009

Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)

Co-investigator, 2008–2012

Randomized, placebo controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion

Co-investigator, 2008–2010

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with DME secondary to diabetic retinopathy

Co-investigator, 2008–2010

Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)

Co-investigator, 2007–2008

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial

Co-investigator, 2007–2008

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 μ g dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema

Co-investigator, 2007–2010

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2007–2012

COBALT: COmbining Bevasiranib And Lucentis Therapy. *A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)*

Co-investigator, 2007–2008

Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)

Co-investigator, 2007–2009

OMEGA: a randomized, double-masked, dose-ranging, multi-center, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2007–2009

Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2007

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC): Comparison of PHP (Preferential Hyperacuity Perimetry) with supervised Amsler grid in detecting neovascular AMD in eyes at high risk for CNV

Co-investigator, 2007–2009

Sirion Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration

Co-investigator, 2007–2010

Natural history observation and registry for macular telangiectasia

Co-investigator, 2006–

A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema

Co-investigator, 2006–2007

Eyetech 1023: Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement

Co-investigator, 2006–2008

Protein Kinase C β Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema

Co-investigator, 2006–2010

Protein Kinase C β Inhibitor Study B7A-MC-MBCU. Effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography

Co-investigator, 2006–2011

A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization secondary to age-related macular degeneration (SAILOR)

Co-investigator, 2006–2007

A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, Memphis (Tennessee) Center, 2005–2006

Other Research Activities

Evaluation of hydroxychloroquine retinopathy with multifocal electroretinogram

Co-investigator, Joslin Diabetes Center, Boston MA, 2003–2004

Evaluation of patients with fifty or more years of insulin dependent diabetes mellitus

Co-investigator, Joslin Diabetes Center, Boston MA, 2003–2004

Study of genes and enzymes responsible for diabetic retinopathy

Co-investigator, Joslin Diabetes Center, Boston MA, 2003

Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study

Co-investigator, Retina Associates of Cleveland, 2002

Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study

Co-investigator, University Hospitals of Cleveland-CWRU, 2001

Treatment of serous retinal detachments in optic nerve head pits with periocular steroids and carbonic anhydrase inhibitors: case studies

Co-investigator, Retina Associates of Cleveland, 2001

Measurement of corneal thickness changes after prolonged swimming with goggles

Medical student, Loyola Medical Center; Department of Ophthalmology,
Maywood IL, 1998

I-CAM expression on bone marrow stromal cells

Research assistant, Loyola-Stritch School of Medicine; Department of
Burn-Shock & Trauma Institute, Maywood IL, 1996

Abbott Laboratories; Department of Research & Development, North Chicago IL

Research Assistant, 1995

United States Construction Engineering Research Laboratory, Champaign IL

Environmental Research Assistant, 01/94–12/94

The Dow Chemical Company; Department of Analytical Section, Midland MI
Analytical Science Intern in X-Ray Fluorescence, 05/94–08/94

SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

Anti-VEGF vs. steroids for diabetic macular edema

Management of chronic diabetic macular edema with vitreomacular traction

Management of chronic pigment epithelial detachments

- Focus 2016 Medical Conference, sponsored by the American Academy of Ophthalmology
Dubai, United Arab Emirates
November 4–5, 2016

Update on the Affordable Care Act: fulfilled dreams or broken promises?

- Moderator, National Medical Association Symposium
- American Academy of Ophthalmology Meeting; Chicago, Illinois
October 17, 2016

Update on treatment of diabetic macular edema

- Optometric Retinal Update; Youngstown, Ohio
September 7, 2016

The OASIS Trial: natural history of symptomatic vitreomacular adhesion

- American Society of Retina Specialists Meeting; San Francisco, California
August 16, 2016

Update on treatment of diabetic macular edema

- American Eye Study Club Meeting; Amelia Island, Florida
August 5, 2016

Diabetic retinopathy

- Retinal Vascular Foundation Seminar; Cleveland, Ohio
June 11, 2016

Diabetes and diabetic retinopathy

- AGF Senior Ministry Diabetes Education Forum; Cleveland, Ohio
June 11, 2016

Vitreoretinal disorders

- Optometric Retinal Update; Akron, Ohio
April 6, 2016

Update on treatment of diabetic retinopathy

- Optometric Retinal Update; Akron, Ohio
November 4, 2015

Vitreoretinal disorders

- Optometric Retinal Update; Warren, Ohio
September 1, 2015

Moderator, Roman Barnes Distinguished Lecture and Meet the Experts panel discussion

Chairperson, Executive, Planning, and Section Business Committee meetings

Video demonstration, vitrectomy combined with Ahmed valve placement for retinal vein occlusion and neovascular glaucoma

- National Medical Association Annual Convention & Scientific Assembly; Detroit, Michigan
August 1-5, 2015

The emerging role of physician assistants in vitreoretinal medicine and surgery

- American Eye Study Club Meeting; Mackinac Island, Michigan
July 30, 2015

“What Would You Do?” case presentations and discussion

- Vit-Buckle Breakfast Symposium, Vit-Buckle Society Meeting; Miami, Florida
March 20, 2015

Vitreoretinal disorders

- Optometric Retinal Update; Beachwood, Ohio
March 12, 2015

Vitreoretinal diseases

- Optometric Retinal Update; Warren, Ohio
September 16, 2014

Current management of vitreomacular interface disorders

- National Medical Association Annual Convention & Scientific Assembly; Honolulu, Hawaii
August 2-6, 2014

First year experience with ocriplasmin

- American Eye Study Club Meeting; Vail, Colorado
July 23, 2014

Early detection of macular degeneration

Perils and pitfalls of ocriplasmin/Jetrea

- Mediterranean Retina VI / Turkish Ophthalmology Society Meeting; Izmir, Turkey
June 2014

Screening and early detection of age-related macular degeneration

Update on treatments for retinal diseases

- Optometric Retinal Update; New Castle, Pennsylvania
December 4, 2013

Retina case presentations

- Optometric Retinal Update; Beachwood, Ohio
September 10, 2013

Patient selection for ocriplasmin

- American Eye Study Club Annual Meeting; Atlantis Resort, Paradise Island, Bahamas
August 2, 2013

Update on treatments for retinal diseases

- Optometric Retinal Update; Beachwood, Ohio
March 14, 2013

Guest Speaker

- Black History Month Program, Jefferson Elementary School, Warren, Ohio
February 4, 2013

Retinal update on anti-VEGF therapy (with Drs. Miller, Novak, Rao, Schartman, and Zegarra)

- Ophthalmologists' Update Seminar. Vermilion, Ohio
December 20, 2012

Unilateral progressive hyperopia

- Mayo Clinic Retina Update and Case Conference, Rochester, Minnesota
September 21, 2012

Safety and efficacy of ranibizumab treatment for diabetic macular edema

- Optometric Retinal Update; Youngstown, Ohio
September 20, 2012

Retinal update on anti-VEGF therapy (with Drs. Miller, Novak, Rao, Schartman, and Zegarra)

- Ophthalmologists' Update Seminar. Vermilion, Ohio
August 12, 2012

Co-moderator, Retina Symposium

Panelist, Where's the evidence? Review of the Comparisons of Age-related Macular Degeneration Trials (CATT): A comparison of Lucentis and Avastin for the treatment of wet age-related macular degeneration (AMD)

- National Medical Association Annual Meeting; New Orleans, Louisiana
July 30, 2012

Genetic testing and macular degeneration

- American Eye Study Club Annual Meeting; The Grand Del Mar Resort, San Diego, California
August 1, 2012

Surgical management of epiretinal membranes

- 5th Mediterranean Retina Meeting and 16th Afro-Asian Congress of Ophthalmology; Istanbul, Turkey
June 16, 2012

Surgical management of epiretinal membranes

- Optometric Retinal Update; Beachwood, Ohio
March 15, 2012

Hereditary retinal disorders: Newly diagnosed, now what?

- Foundation Fighting Blindness, Cleveland Leadership Call Speaker Series; Cleveland, Ohio
December 3, 2011

Moderator, Retina Symposium

Speaker, 1) Epiretinal membranes; 2) Chronic central serous chorioidopathy.

- Croatian Ophthalmological Society; Dubrovnik, Croatia
October 2011

Assessment and management of epiretinal membranes

- Optometric Retinal Update; Youngstown, Ohio
September 1, 2011

Photodynamic therapy with Visudyne for central serous chorioretinopathy

- American Eye Study Club 54th Annual Meeting – Summer Conference; Pinehurst, North Carolina
July 27, 2011

Moderator, Retina Symposium

Contributor, Surgical Symposium: Small gauge sutureless surgery for complicated retinal diseases

- National Medical Association Annual Convention and Scientific Assembly; Washington, DC
July 26, 2011

Emerging treatments for diabetic retinopathy

- Optometric Retinal Update; Beachwood, Ohio
March 3, 2011

Retina Symposium Moderator

- National Medical Association Annual Convention and Scientific Assembly; Orlando, Florida
August 1, 2010

Brown CC, Coney JM, H. Zegarra H. Results of photodynamic therapy with verteporfin for the treatment of central serous chorioretinopathy.

- Rabb Venable Research Competition
August 1, 2010

Update on diabetic retinopathy

- Optometric Retinal Update; New Castle, Pennsylvania
May 13, 2010

Singerman LJ, Novak MA, Miller DG, Coney JM, et al. Ranibizumab treatment for pigment epithelial detachment (PED) in age-related macular degeneration (AMD).

- Retina Congress 2009, Combined Meeting of the American Society of Retina Specialists, The Macula Society, and The Retina Society; New York, New York
September 30–October 4, 2009

Neovascular peripheral retinal disease

- Optometric Retinal Update; Youngstown, Ohio
August 20, 2009

Retina surgery videos (with David G. Miller, MD)

- National Medical Association Annual Meeting; Las Vegas, Nevada
July 25–29, 2009

Berlon NR, Miller DG, Novak MA, Pendergast SD, Coney JC. Safety and efficacy of 25-gauge vitrectomy surgery by experienced vitreoretinal surgeons.

- Association for Research in Vision and Ophthalmology Annual Meeting. Program # 5202; Fort Lauderdale, Florida.
May 7, 2009

Diabetes and the eye

- Cleveland Ophthalmic Personnel Society; Independence, Ohio
April 19, 2009

Surgical techniques for epiretinal membrane removal

- Retinal Update for Ophthalmologists; Youngstown, Ohio
March 18, 2009

Photodynamic therapy for central serous chorioretinopathy

- Cleveland Ophthalmological Society; Cleveland, Ohio
February 10, 2009

Posterior complications of anterior segment surgery

- Optometric Retinal Update; Youngstown, Ohio
September 18, 2008

Posterior complications of anterior segment surgery

- National Medical Association Annual Meeting; Atlanta, Georgia
July 2008

Open forum presentation, Eye Care America; glaucoma screening booth

- Cleveland Medical Association Radio One Health Fair
April 27 & 28, 2008

Newest information on research and treatments for macular degeneration

- Macula Vision Research Foundation SupportSight Seminar, Middleburg Hts, Ohio
April 8, 2008

Diabetic retinopathy

- Optometric Retinal Update; New Castle, Pennsylvania
October 25, 2007

Update on management of macular edema

- Optometric Retinal Update; Youngstown, Ohio
September 5, 2007

Rabb-Venable Fluorescein Angiography Conference

- National Medical Association Annual Meeting; Waikiki, Hawaii
August 2007

Optic nerve head pits

- Cleveland Ophthalmological Society; Cleveland, Ohio
April 10, 2007

Answers to the top 10 questions about macular degeneration

- Macula Vision Research Foundation SupportSight Seminar; Middleburg Hts, Ohio
March 24, 2007

Complications of diabetic retinopathy

- First Annual Chairman's Research Forum, Diabetes Association of Greater Cleveland;
Cleveland, Ohio
Invited Speaker; November 2, 2006

Macular degeneration: causes, copings and cures

- Weils Community Event; Chagrin Falls, Ohio
Invited Speaker; October 10, 2006

Grading diabetic retinopathy

- Optometric Retinal Update; Beachwood, Ohio
September 28, 2006

Grading diabetic retinopathy

- Optometric Retinal Update; Youngstown, Ohio
September 25, 2006

Ophthalmology and systemic diseases: utility of ophthalmologic input for diagnostic and therapeutic purposes

- Southwest Hospital Grand Rounds (CME credit course); Middleburg Hts, Ohio
July 28, 2006

Clinical characteristics of complications in patients with 50 or more years of Type 1 diabetes

- National Medical Association 109th Annual Scientific Section; San Diego, California
August 2004

Management of serous retinal detachments

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India
June 2004

Clinical grading of diabetic retinopathy lecture series/conference

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India
May 2004
- Massachusetts Eye & Ear Infirmary Resident Teaching; Boston, Massachusetts
2003–2004

Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India
May 2004
- Case Western Reserve University Ninth Annual Resident and Alumni Research Day;
Cleveland, Ohio
June 2002

Optic nerve pits: the origin and management of serous retinal detachments

- Longwood Medical Association of Ophthalmology/Harvard Medical School; Boston,
Massachusetts
October 2003
- University Hospitals of Cleveland, Department of Ophthalmology, Grand Rounds
Cleveland, Ohio
June 2003

Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study;

- Aravind Eye Hospital, Department of Ophthalmology; Maduri, India
May 2004
- American Society of Retina Specialists 21st Annual Meeting New York, New York
August 2003
- National Medical Association 108th Annual Scientific Section; Philadelphia, Pennsylvania
August 2003
- Case Western Reserve University Ninth Annual Resident and Alumni Research Day;
Cleveland, Ohio
June 2003

Angioid streaks: the management of CNVM

- Case Western Reserve University Second Annual Residents Day; Cleveland, Ohio
March 2003

Current management of idiopathic parafoveal telangiectasis

- Case Western Reserve University Second Annual Residents Day; Cleveland, Ohio
March 2003

Diagnosis & management of idiopathic polypoidal choroidopathy

- University Hospitals of Cleveland, Department of Ophthalmology, Grand Rounds;
Cleveland, Ohio
February 2003

Ocular manifestations of sarcoidosis

- Case Western Reserve University First Annual Residents Day; Cleveland, Ohio
November 2001

PUBLICATIONS

Journal Articles

1. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:865-875.
2. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology*. 2016;123:609-616.
3. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment. *JAMA Ophthalmol*. 2016;134:278-285.
4. Wells JA, Glassman AR, Jampol LM, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. *JAMA Ophthalmol*. 2016;134:127-134.
5. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*. 2015 Nov 13:1-11.

6. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. *JAMA Ophthalmol*. 2015;133:888-896.
7. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology* 2015;122:1846-1853.
8. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015 Mar 26;372:1193-1203.
9. Friedman SM(1), Almkhatar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M; Diabetic Retinopathy Clinical Research Network. Topical nepafenec in eyes with noncentral diabetic macular edema. *Retina* 2015;35:944-956.
10. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015;159:659-666.
11. Altaweel MM, Daniel E, Martin DF, Mitra RA, Grunwald JE, Lai MM, Melamud A, et al; Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology* 2015;122:391-398.
12. Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2014;121:1956-1965.
13. Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Am J Ophthalmol* 2014;158:128-135.
14. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol* 2014;132:521-527.

15. Rao LJ, Coney JM, Schartman JP, Singerman, LJ. Neovascular AMD: treatment beyond anti-VEGF. *Retinal Physician* 2014;11:23-28.
16. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol* 2013;131:1033-1040.
17. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:1860-1870.
18. Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci* 2013 8;54:4548-4554.
19. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). *Ophthalmology* 2013;120:593-599.
20. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol* 2013;131:283-293.
21. Ying GS, Huang J, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. *Ophthalmology* 2013 Jan;120:122-129.
22. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology* 2012;119:2312-2318.
23. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012;119:1388-1398.
24. Schartman JP, Coney JM, Hornik JH, Miller DG. Pegaptanib octasodium for the treatment of diabetic macular oedema. *Expert Opinion on Pharmacotherapy* 2011;12:1317-1323.
25. Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and

- digital fundus photographs in eyes of individuals with diabetes mellitus. *Invest Ophthalmol Vis Sci* 2011;52:6168-6173.
26. Chan CK, Ip MS, VanVeldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.
 27. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2011 May 19;364:1897-1908. Epub 2011 Apr 28.
 28. Coney JM, Schartman JP, Singerman LJ. Advancing treatments for diabetic macular edema. *Retinal Physician* 2011;8:40, 43-44, 46.
 29. Diabetic Retinopathy Clinical Research Network; Writing Committee, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011;118:609-614.
 30. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina* 2010;30:1488-1495.
 31. Coney JM, Miller DG. Epiretinal membrane. *Focal Points*. Volume XXVII, Number 5, American Academy of Ophthalmology, 2009.
 32. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. *Am J Ophthalmol* 2009;148:725-732.
 33. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
 34. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
 35. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.

36. Patronas M, Coney JM, Singerman LJ. Treating neovascular peripheral retinal diseases. *Retinal Physician* 2008;5(8):53,54,56,58.
37. Coney JM, Novak MA, Zegarra H. New treatments for diabetic macular edema. *MD News* 2008; 12 (2):32, 34.
38. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology* 2008;115:1366-1371, 1371.e1.
39. Coney JM, Singerman LJ. Patient management in intravitreal injections. *Retinal Physician* 2007;4:52,55.
40. Keenan HA, Costacou T, Doria A, Coney JM, Orchard TJ, Aiello LP, King GL. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the fifty-year medalist study. *Diabetes Care* 2007;30:1995-1997.
41. Jager RI, Timothy NH, Coney JM, Katalinic P, Cavicchi RW, Strong J, Cavallerano JD, Aiello LP. Congenital retinal macrovessel. *Retina, The Journal of Retinal and Vitreous Diseases* 2005;25:538-540.
42. Gurelik G, Coney JM, Zakov ZN. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *Ophthalmic Surg Lasers Imaging* 2004;35:94-102.
43. Kopstein A, Coney J, Bouchard CS. Corneal pachymetric and biomicroscopic changes after swimming with and without goggles: A prospective study. *Invest Ophthalmol Vis Sci* 1999;39:S913.

Posters

1. Rostamizadeh M, Abdelaziz M, Patel A, Moarefi M, Miller D, Coney J, Novak M, Rao L, Pendergast S, Singerman L. Incidence of endophthalmitis in various anti-VEGF treatments. Scientific Poster 5025/ B0231, Association for Research in Vision and Ophthalmology Annual Meeting, May 2016.
2. O'Neill B, Shah A, Coney JM. Resolution of vitreomacular traction using Jetrea and its potential role in diabetic macular edema (with). Poster 294/B0272. Association for Research in Vision and Ophthalmology Annual Meeting. Orlando, Florida, May 2014.
3. Singerman LJ, Himmelman DR, Singerman B, Thomas A, Newman L, Coney JM, Schartman JP, Novak MA. Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion. Poster 5466/A662. Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, Florida, May 2012.

4. Brown CC, Coney JM, Zegarra H. Results of photodynamic therapy with verteporfin for the treatment of central serous chorioretinopathy. Association for Research in Vision and Ophthalmology Annual Meeting. Program # 1341 / Poster #A354. Fort Lauderdale, Florida. May 3, 2010.
5. Clinical characteristics of complications in patients with 50 or more years of Type 1 diabetes; American Diabetes Association 64th Annual Scientific Section. Orlando, Florida; June 2004.
6. Evaluation of insulin dependent diabetic patients with more than fifty years of diabetes. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida; April 2004.
7. Endophthalmitis as a complication of intravitreal injection: a systemic review. Association for Research in Vision and Ophthalmology. Fort Lauderdale, Florida; April 2004.
8. Evaluation of photocoagulation for macular edema in hemi-retinal vein occlusion: a retrospective study. Association for Research in Vision and Ophthalmology Fort Lauderdale, Florida; May 2002
9. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study
 - Retina Society 36th Scientific Session; Chicago, Illinois; September 2003
 - Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida; May 2003
6. Measurement of corneal thickness changes after prolonged swimming with goggles. Association for Research in Vision and Ophthalmology; Fort Lauderdale, Florida; March 1999
7. I-CAM expression on bone marrow stromal cells
 - National Medical Research Forum; Galveston, Texas; April 1997
 - Student National Medical Association & National Institutes of Health; New Orleans, Louisiana; March 1997
 - Midwest Student Medical Research Forum; Omaha, Nebraska; February 1997
 - St. Luke's Research Forum, Loyola-Stritch School of Medicine; Maywood, Illinois; October 1996